We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

May 20, 2019

87th EAS Congress

05 - LIPID-LOWERING RESPONSE IN SUBJECTS WITH THE P.(LEU167DEL) MUTATION IN APOE GENE

;

APOE

p.(Leu167del)

familial hypercholesterolemia

lipid-lowering treatment

Abstract

15

Views

15

Views

Abstract

Fullscreen

thumbnail

Keywords

APOE

p.(Leu167del)

familial hypercholesterolemia

lipid-lowering treatment

Abstract

Background and aim The aim of this work was to compared the effect of lipid lowering drugs among FH subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE. Methods We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n=22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n=44). Results The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4 % and -36.4%, respectively (p = 0.030). Conclusions Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for more efficient management of FH.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.